Fludarabina Teva 25 mg/ml concentrado para solución para perfusión o inyección EFG
Sponsors
Cellectis, Iovance Biotherapeutics Inc., Fundacio Institut D Investigacio Biomedica De Bellvitge IDIBELL, Vall D Hebron Institute Of Oncology, Cabaletta Bio Inc.
Conditions
Active Idiopathic Inflammatory Myopathy including dermatomyositisActive Systemic Lupus Erythematosus;Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder characterized by
autoantibody production and abnormal B cell function. SLE presents with fluctuating severity
and may cause tissue damage in a variety of organs over time. Lupus nephritis (LN) is a common
severe manifestation of SLEAdvanced selected solid tumors: melanomaAdvanced solid tumorsMelanomaMetastatic Non-Small-Cell Lung CancerRelapsed or refractory B cell acute lymphoblastic leukaemiaRelapsed or refractory B-cell Non-Hodgkin lymphoma
Phase 1
Open-label dose-finding and dose-expansion study to evaluate the safety, expansion, persistence, and clinical activity of UCART20x22 in subjects with relapsed or refractory B-cell Non-Hodgkin Lymphoma (B-NHL)
RecruitingCTIS2022-501607-27-00
Start: 2026-01-06Target: 48Updated: 2026-01-08
An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating the Safety and Efficacy of AUTO1, a CAR T Cell Treatment Targeting CD19, in Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia.
Active, not recruitingCTIS2024-512903-38-00
Start: 2021-12-01Target: 17Updated: 2025-12-17
A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Subjects with Active Systemic Lupus Erythematosus
RecruitingCTIS2023-507613-10-01
Start: 2025-03-31Target: 6Updated: 2026-01-26
A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Subjects with Active Idiopathic Inflammatory Myopathy or Active Juvenile Idiopathic Inflammatory Myopathy
Not yet recruitingCTIS2025-521145-24-01
Target: 13Updated: 2026-04-30
Phase 2
A phase 2, Multicenter Study of TILs Treatment in Advanced Tumors with Alterations in the SWI/SNF Complex: the TILTS Study
RecruitingCTIS2023-504632-17-00
Start: 2024-08-14Target: 11Updated: 2025-08-19
A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Metastatic Non-Small-Cell Lung Cancer
RecruitingCTIS2024-510778-26-00
Start: 2025-12-19Target: 115Updated: 2025-11-26
Phase II randomized study evaluating a Pragmatic approach to Adoptive Cell Therapy (ACT) using an IL2 analog (ANV419) vs High dose IL2 after Tumor Infiltrating Lymphocytes (TIL) Therapy in patients with melanoma, NSCLC and cervical cancer. The PragmaTIL
RecruitingCTIS2023-506400-99-00
Start: 2025-01-15Target: 24Updated: 2025-12-02